Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2018 Oct 25. doi: 10.1002/cncr.31811. [Epub ahead of print]

PMID:
30359477
2.

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF.

J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12.

3.

The Pluto system: Initial results from its exploration by New Horizons.

Stern SA, Bagenal F, Ennico K, Gladstone GR, Grundy WM, McKinnon WB, Moore JM, Olkin CB, Spencer JR, Weaver HA, Young LA, Andert T, Andrews J, Banks M, Bauer B, Bauman J, Barnouin OS, Bedini P, Beisser K, Beyer RA, Bhaskaran S, Binzel RP, Birath E, Bird M, Bogan DJ, Bowman A, Bray VJ, Brozovic M, Bryan C, Buckley MR, Buie MW, Buratti BJ, Bushman SS, Calloway A, Carcich B, Cheng AF, Conard S, Conrad CA, Cook JC, Cruikshank DP, Custodio OS, Dalle Ore CM, Deboy C, Dischner ZJ, Dumont P, Earle AM, Elliott HA, Ercol J, Ernst CM, Finley T, Flanigan SH, Fountain G, Freeze MJ, Greathouse T, Green JL, Guo Y, Hahn M, Hamilton DP, Hamilton SA, Hanley J, Harch A, Hart HM, Hersman CB, Hill A, Hill ME, Hinson DP, Holdridge ME, Horanyi M, Howard AD, Howett CJ, Jackman C, Jacobson RA, Jennings DE, Kammer JA, Kang HK, Kaufmann DE, Kollmann P, Krimigis SM, Kusnierkiewicz D, Lauer TR, Lee JE, Lindstrom KL, Linscott IR, Lisse CM, Lunsford AW, Mallder VA, Martin N, McComas DJ, McNutt RL Jr, Mehoke D, Mehoke T, Melin ED, Mutchler M, Nelson D, Nimmo F, Nunez JI, Ocampo A, Owen WM, Paetzold M, Page B, Parker AH, Parker JW, Pelletier F, Peterson J, Pinkine N, Piquette M, Porter SB, Protopapa S, Redfern J, Reitsema HJ, Reuter DC, Roberts JH, Robbins SJ, Rogers G, Rose D, Runyon K, Retherford KD, Ryschkewitsch MG, Schenk P, Schindhelm E, Sepan B, Showalter MR, Singer KN, Soluri M, Stanbridge D, Steffl AJ, Strobel DF, Stryk T, Summers ME, Szalay JR, Tapley M, Taylor A, Taylor H, Throop HB, Tsang CC, Tyler GL, Umurhan OM, Verbiscer AJ, Versteeg MH, Vincent M, Webbert R, Weidner S, Weigle GE 2nd, White OL, Whittenburg K, Williams BG, Williams K, Williams S, Woods WW, Zangari AM, Zirnstein E.

Science. 2015 Oct 16;350(6258):aad1815. doi: 10.1126/science.aad1815.

4.

Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors.

Bankson JA, Walker CM, Ramirez MS, Stefan W, Fuentes D, Merritt ME, Lee J, Sandulache VC, Chen Y, Phan L, Chou PC, Rao A, Yeung SC, Lee MH, Schellingerhout D, Conrad CA, Malloy C, Sherry AD, Lai SY, Hazle JD.

Cancer Res. 2015 Nov 15;75(22):4708-17. doi: 10.1158/0008-5472.CAN-15-0171. Epub 2015 Sep 29.

5.

PD-L1 expression and prognostic impact in glioblastoma.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB.

Neuro Oncol. 2016 Feb;18(2):195-205. doi: 10.1093/neuonc/nov172. Epub 2015 Aug 30.

6.

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ.

Clin Cancer Res. 2015 Oct 15;21(20):4630-41. doi: 10.1158/1078-0432.CCR-14-3195. Epub 2015 Jun 23.

7.

Genetic Modulation of Neurocognitive Function in Glioma Patients.

Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS.

Clin Cancer Res. 2015 Jul 15;21(14):3340-6. doi: 10.1158/1078-0432.CCR-15-0168. Epub 2015 Apr 22.

8.

Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.

Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S.

Oncotarget. 2015 Apr 30;6(12):10016-29.

9.

Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.

Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J.

Curr Opin Virol. 2015 Aug;13:33-9. doi: 10.1016/j.coviro.2015.03.009. Epub 2015 Apr 13. Review.

10.

Therapeutic targets in subependymoma.

Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB.

J Neuroimmunol. 2014 Dec 15;277(1-2):168-75. doi: 10.1016/j.jneuroim.2014.10.008. Epub 2014 Oct 31.

PMID:
25465288
11.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative.

Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19.

12.

Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again.

Conrad CA, Fueyo J, Gomez-Manzano C.

Neuro Oncol. 2014 Aug;16(8):1025-6. doi: 10.1093/neuonc/nou121. Epub 2014 Jul 6. No abstract available.

13.

Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.

Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C.

Oncotarget. 2014 Apr 30;5(8):2208-20.

14.

Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF.

J Neurooncol. 2014 Aug;119(1):135-40. doi: 10.1007/s11060-014-1460-z. Epub 2014 May 7.

15.

Pregnancy and glial brain tumors.

Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS.

Neuro Oncol. 2014 Sep;16(9):1289-94. doi: 10.1093/neuonc/nou019. Epub 2014 Mar 9.

16.

Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines.

Lichti CF, Liu H, Shavkunov AS, Mostovenko E, Sulman EP, Ezhilarasan R, Wang Q, Kroes RA, Moskal JC, Fenyö D, Oksuz BA, Conrad CA, Lang FF, Berven FS, Végvári A, Rezeli M, Marko-Varga G, Hober S, Nilsson CL.

J Proteome Res. 2014 Jan 3;13(1):191-9. doi: 10.1021/pr400786s. Epub 2013 Dec 3.

PMID:
24266786
17.

Integrative biological analysis for neuropsychopharmacology.

Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL.

Neuropsychopharmacology. 2014 Jan;39(1):5-23. doi: 10.1038/npp.2013.156. Epub 2013 Jun 26. Review.

18.

Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.

Nilsson CL, Berven F, Selheim F, Liu H, Moskal JR, Kroes RA, Sulman EP, Conrad CA, Lang FF, Andrén PE, Nilsson A, Carlsohn E, Lilja H, Malm J, Fenyö D, Subramaniyam D, Wang X, Gonzales-Gonzales M, Dasilva N, Diez P, Fuentes M, Végvári Á, Sjödin K, Welinder C, Laurell T, Fehniger TE, Lindberg H, Rezeli M, Edula G, Hober S, Marko-Varga G.

J Proteome Res. 2013 Jan 4;12(1):135-50. doi: 10.1021/pr3008607. Epub 2012 Dec 18.

19.

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. doi: 10.1007/s00280-012-1854-6. Epub 2012 Mar 7.

20.

Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.

Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK.

Cancer. 2012 Jul 15;118(14):3599-606. doi: 10.1002/cncr.26663. Epub 2011 Nov 15.

21.

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM.

Cancer. 2011 Nov 1;117(21):4939-47. doi: 10.1002/cncr.26098. Epub 2011 Apr 8.

22.

Determining and interpreting correlations in lipidomic networks found in glioblastoma cells.

Görke R, Meyer-Bäse A, Wagner D, He H, Emmett MR, Conrad CA.

BMC Syst Biol. 2010 Sep 7;4:126. doi: 10.1186/1752-0509-4-126.

23.

Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA.

J Neurooncol. 2011 Apr;102(2):273-80. doi: 10.1007/s11060-010-0313-7. Epub 2010 Jul 23.

24.

Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.

He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA.

J Proteome Res. 2010 May 7;9(5):2098-108. doi: 10.1021/pr900793a.

PMID:
20199106
25.

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA.

Neuro Oncol. 2010 Mar;12(3):233-42. doi: 10.1093/neuonc/nop027. Epub 2010 Jan 6.

26.

Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.

Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA.

J Proteome Res. 2010 Jan;9(1):430-43. doi: 10.1021/pr9007927.

PMID:
19899826
27.

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK.

Br J Cancer. 2009 Aug 18;101(4):615-20. doi: 10.1038/sj.bjc.6605189.

28.

Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.

He H, Nilsson CL, Emmett MR, Ji Y, Marshall AG, Kroes RA, Moskal JR, Colman H, Lang FF, Conrad CA.

Glycoconj J. 2010 Jan;27(1):27-38. doi: 10.1007/s10719-009-9249-6. Epub 2009 Jun 26.

PMID:
19557511
29.

Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.

Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ.

J Neurooncol. 2009 Sep;94(2):229-34. doi: 10.1007/s11060-009-9819-2. Epub 2009 Mar 7.

PMID:
19267183
30.

Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.

Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J.

Cancer Gene Ther. 2009 Mar;16(3):256-65. doi: 10.1038/cgt.2008.75. Epub 2008 Oct 17.

31.

VEGF Trap induces antiglioma effect at different stages of disease.

Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK.

Neuro Oncol. 2008 Dec;10(6):940-5. doi: 10.1215/15228517-2008-061. Epub 2008 Aug 14.

32.

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.

Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK.

Neuro Oncol. 2008 Apr;10(2):208-15. doi: 10.1215/15228517-2007-059. Epub 2008 Mar 3.

33.

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK.

Neuro Oncol. 2008 Apr;10(2):216-22. doi: 10.1215/15228517-2007-060. Epub 2008 Feb 26.

34.

Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells.

He H, Conrad CA, Nilsson CL, Ji Y, Schaub TM, Marshall AG, Emmett MR.

Anal Chem. 2007 Nov 15;79(22):8423-30. Epub 2007 Oct 12.

35.

Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression.

Puchades M, Nilsson CL, Emmett MR, Aldape KD, Ji Y, Lang FF, Liu TJ, Conrad CA.

J Proteome Res. 2007 Feb;6(2):869-75.

PMID:
17269744
36.

Effect of bevacizumab on radiation necrosis of the brain.

Gonzalez J, Kumar AJ, Conrad CA, Levin VA.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6.

PMID:
17236958
37.

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK.

J Neurooncol. 2007 Feb;81(3):271-7. Epub 2006 Sep 22.

PMID:
17031561
38.

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA.

J Neurooncol. 2006 Oct;80(1):83-90. Epub 2006 Apr 25.

PMID:
16639492
39.

Mechanisms of action of rapamycin in gliomas.

Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF.

Neuro Oncol. 2005 Jan;7(1):1-11.

40.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.

Mol Cancer Ther. 2005 Jan;4(1):101-12.

41.

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M; North American Brain Tumor Consortium.

J Clin Oncol. 2004 Nov 1;22(21):4282-9.

42.

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.

Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J.

Oncogene. 2004 Mar 11;23(10):1821-8.

PMID:
15014451
43.

Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.

Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ.

Int J Oncol. 2004 Feb;24(2):409-17.

PMID:
14719118
44.

Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.

Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF.

J Natl Cancer Inst. 2003 May 7;95(9):652-60.

PMID:
12734316
45.

Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis.

Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK.

Ann Neurol. 2003 Jan;53(1):109-17.

PMID:
12509854
46.

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA.

Neuro Oncol. 2002 Oct;4(4):268-77. doi: 10.1093/neuonc/4.4.268.

47.

Chemotherapy for metastatic tumors to the central nervous system.

Conrad CA.

Curr Oncol Rep. 2001 Nov;3(6):490-4. Review.

PMID:
11595117
48.

Examination of factor structure for the consumers' responses to the Value Consciousness Scale.

Conrad CA, Williams JR.

Psychol Rep. 2000 Dec;87(3 Pt 2):1133-8.

PMID:
11272753
49.

Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.

Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ.

Anticancer Drugs. 1998 Jun;9(5):405-9.

PMID:
9660537
50.

Neurotoxicity of CI-980, a novel mitotic inhibitor.

Meyers CA, Kudelka AP, Conrad CA, Gelke CK, Grove W, Pazdur R.

Clin Cancer Res. 1997 Mar;3(3):419-22.

Supplemental Content

Loading ...
Support Center